Nektar Therapeutics
NKTR
Real-time BATS EXCHANGE - 09/24 09:29:03 pm
61.305USD
+3.88%
Prev.59.0000
Open58.4100
High62.7000
Low58.3000
Volume4 644 429
Financials
Sales 2018 1 181 M
EBIT 2018 692 M
R. net 2018 669 M
Tréso. 2018 469 M
Rend. 2018 -
P/E ratio 2018 15,55
P/E ratio 2019
Capi. / Sales 2018 8,22x
Capi. / Sales 2019 34,4x
Capitalization 10 176 M
Company
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms.It operates through the United States and Europe geogrpahical segments.The company was founded in 1990 and is...
Sector :
Biotechnology & Medical Research - NEC
Calendar :
2018-10-22 Presentation
Trading Rating :
Investor Rating :
Latest news
01:01pNEKTAR THERAPEUTICS : BioXcel Therapeutics Expands Immuno-Oncology Partnership with Nektar into Clinical Development in Pancreatic Cancer
AQ
09/14S&P 500 MOVERS : Ni, adbe
AQ
09/13NEKTAR THERAPEUTICS : "Oligomer-Phenothiazine Conjugates" in Patent Application Approval Process (USPTO 20180243429)
AQ
09/05NEKTAR THERAPEUTICS : Today's Research Reports on Trending Tickers: Cronos Group and Nektar Therapeutics
AC
08/16S&P 500 MOVERS : Nktr, wmt
AQ
08/10NEKTAR THERAPEUTICS : U.S. Patents Awarded to Inventors in Alabama (Aug. 10)
AQ
08/09NEKTAR THERAPEUTICS : New Findings from Nektar Therapeutics in the Area of Breast Cancer Described (Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects...
AQ
08/09NEKTAR THERAPEUTICS : Patent Issued for Heterobifunctional Poly(Ethylene Glycol) Derivatives And Methods For Their Preparation (USPTO 10,035,880)
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishBearishNeutral
Resistance63,372,0108
Spread/Res.-3,2%-15%-43%
Spread/Supp.8,2%33%164%
Support56,746,323,2